<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin van den Bent, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn A Tung, MD, FACR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are significant differences between oligodendrogliomas and other glial tumors in pathology, molecular pathogenesis, and natural history. These differences have important prognostic implications, which can affect treatment.</p><p>In the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase (IDH) type 1 or type 2 and codeletion of chromosomes 1p and 19q [<a href="#rid1">1</a>]. Mixed oligoastrocytoma no longer exists for fully characterized tumors, but the terminology is retained when referring to historically diagnosed tumors and for tumors with mixed oligoastrocytoma histology for which molecular testing is not available (ie, oligoastrocytoma not otherwise specified [NOS]). (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>.)</p><p>The clinical manifestations, classification, pathologic classification, and molecular prognostic factors associated with IDH-mutant, 1p/19q-codeleted oligodendrogliomas (grades 2 and 3) will be reviewed here. The treatment of these tumors is discussed separately. (See  <a class="medical medical_review" href="/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a> and  <a class="medical medical_review" href="/d/html/5221.html" rel="external">"Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults"</a>.)</p><p class="headingAnchor" id="H58065116"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Oligodendroglial tumors are rare tumors, constituting approximately 5 percent of all malignant primary tumors of the central nervous system [<a href="#rid2">2</a>]. Together, grade 2 and 3 oligodendrogliomas are one-tenth as common as glioblastoma, the most commonly occurring malignant primary brain tumor in adults. Approximately 1000 oligodendroglial tumors are diagnosed in the United States each year, with an age-adjusted incidence of 0.27 per 100,000 people [<a href="#rid2">2</a>].</p><p>Environmental and genetic risk factors for primary brain tumors are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5214.html" rel="external">"Risk factors for brain tumors"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1554344620"><span class="h2">Age of onset</span><span class="headingEndMark"> — </span>Most oligodendrogliomas present in adults between 25 and 50 years of age. The median age at diagnosis is 43 years for World Health Organization (WHO) grade 2 tumors and approximately 5 to 10 years late for WHO grade 3 tumors [<a href="#rid2">2</a>]. Oligodendrogliomas are occasionally diagnosed in teenagers and in adults over the age of 65 years [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Oligodendrogliomas are slowly-growing, infiltrative tumors that may be clinically silent for many years. The most common presenting symptom is seizure, which can be focal or evolving to a bilateral convulsive (secondarily generalized) seizure. Some patients are asymptomatic and diagnosed based on incidental findings at the time of brain imaging performed for another reason (eg, trauma, migraine headaches).</p><p>Focal neurologic deficits and generalized symptoms such as headache are uncommon at the time of diagnosis. As tumors progress, symptoms vary based on tumor location, size, and rate of tumor growth. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>.)</p><p>Most oligodendroglial tumors arise in the white matter of the cerebral hemispheres, predominantly in the frontal lobes [<a href="#rid4">4</a>]. Rarely, they arise at infratentorial sites and in the spinal cord [<a href="#rid5">5</a>]. A multifocal, gliomatosis pattern of involvement can be seen, although it is more commonly associated with astrocytic histology. Leptomeningeal spread can occur but is typically a late development.</p><p>As with other glial tumors, oligodendrogliomas only rarely metastasize outside the central nervous system.</p><p class="headingAnchor" id="H5"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>On magnetic resonance imaging (MRI), most low-grade oligodendrogliomas have hyperintense or mixed signal on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images and hypointense or mixed signal intensity on T1-weighted images  (<a class="graphic graphic_diagnosticimage graphicRef113599" href="/d/graphic/113599.html" rel="external">image 1</a>) [<a href="#rid6">6</a>]. Compared with isocitrate dehydrogenase (IDH)-mutant diffuse astrocytomas, oligodendrogliomas are more likely to have indistinct borders  (<a class="graphic graphic_diagnosticimage graphicRef140794" href="/d/graphic/140794.html" rel="external">image 2</a>), involve the gray matter, and have nonuniform signal on T1- and T2-weighted images [<a href="#rid7">7-9</a>]. They lack the so-called T2/FLAIR mismatch sign, which can be seen in IDH-mutant astrocytomas  (<a class="graphic graphic_diagnosticimage graphicRef140796" href="/d/graphic/140796.html" rel="external">image 3</a>). (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Low-grade glioma'</a>.)</p><p>Calcifications, which are characteristic of oligodendroglial tumors but not highly sensitive or specific, are well visualized on computed tomography (CT) and can be seen as low signal intensity on T2-weighted images and dark signal on susceptibility-weighted sequences  (<a class="graphic graphic_diagnosticimage graphicRef140794" href="/d/graphic/140794.html" rel="external">image 2</a>) [<a href="#rid7">7</a>].</p><p>Most grade 3 oligodendrogliomas are associated with some contrast enhancement, which presumably reflects microvascular proliferation and blood-brain barrier leakage  (<a class="graphic graphic_diagnosticimage graphicRef140794" href="/d/graphic/140794.html" rel="external">image 2</a>). However, the absence of contrast enhancement does not exclude anaplastic histopathology, nor does its presence exclude low-grade (grade 2) histopathology. Up to 50 percent of low-grade oligodendrogliomas have some faint contrast enhancement.</p><p>On the whole, none of these imaging findings is sufficiently specific in clinical practice to replace histopathologic examination to establish both the tumor type and grade. Sampling error, particularly in patients who undergo only a biopsy, can lead to misclassification and undergrading of a brain tumor. The neuroimaging characteristics of a lesion may guide the surgeon in choosing a site for biopsy, and the presence of enhancement is suggestive of a high-grade tumor.</p><p class="headingAnchor" id="H2268108800"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients with a suspected infiltrative glioma should undergo history, neurologic examination, and brain magnetic resonance imaging (MRI) with contrast. Additional tests, such as lumbar puncture and magnetic resonance spectroscopy, are not routinely indicated but can provide useful information in selected cases, such as when a demyelinating process is being considered on the differential diagnosis. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Initial evaluation'</a>.)</p><p>Accurate diagnosis of oligodendroglioma and other infiltrative gliomas requires an adequate tissue sample for histopathologic and molecular study. This may be obtained by stereotactic biopsy for deep-seated tumors or at the time of maximal safe resection for tumors in accessible locations. Patients should be referred to a neurosurgeon with subspecialty expertise in brain tumor neurosurgery when possible. Procedure selection is individualized based on suspected tumor type and grade, location, and operability. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Oligodendrogliomas are genetically defined, diffusely infiltrating gliomas that contain both an <em>IDH1</em> or <em>IDH2</em> mutation and whole-arm codeletion of chromosomes 1p and 19q  (<a class="graphic graphic_algorithm graphicRef134946" href="/d/graphic/134946.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef134980" href="/d/graphic/134980.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Although the most typical histopathologic appearance is that of oligodendroglioma, microscopically, tumors may have astrocytic features as well.</p><p class="headingAnchor" id="H7"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Oligodendrogliomas are histologically well-differentiated, diffusely infiltrating tumors composed predominantly of cells resembling oligodendrocytes [<a href="#rid10">10,11</a>].</p><p>The classic appearance is that of sheets of isomorphic round nuclei surrounded by clear cytoplasm ("fried egg" appearance)  (<a class="graphic graphic_picture graphicRef65601" href="/d/graphic/65601.html" rel="external">picture 1</a>). Delicate, branching capillaries and microcalcifications are typical. More elongated, astrocytic tumor cells can be present and are compatible with the diagnosis of oligodendroglioma; it is the presence of an <em>IDH1/2</em> mutation and 1p/19q codeletion that defines an oligodendroglioma [<a href="#rid12">12</a>]. If mixed oligoastrocytic histology is present and genetic testing cannot be performed, such a tumor is diagnosed provisionally as oligoastrocytoma not otherwise specified (NOS). (See <a class="local">'Tumors previously called oligoastrocytoma'</a> below.)</p><p>The World Health Organization (WHO) grading system distinguishes two histopathologic grades of oligodendroglioma: grade 2 (low-grade) and grade 3 (anaplastic) oligodendroglioma [<a href="#rid1">1</a>]. Grade 3 tumors are characterized by the presence of anaplastic features (high cell density, mitosis, nuclear atypia, microvascular proliferation, and necrosis) and are associated with modestly worse prognosis compared with grade 2 tumors.</p><p>The natural history of oligodendrogliomas is a gradual progression from low-grade (well-differentiated) tumors into high-grade lesions with anaplastic features. These morphologic changes appear gradually within a tumor, and an objective distinction between oligodendroglioma (low-grade) and anaplastic oligodendroglioma (high-grade) is not always possible. Some patients present with an anaplastic oligodendroglioma without evidence of a prior low-grade lesion.</p><p class="headingAnchor" id="H9"><span class="h2">Key molecular alterations</span><span class="headingEndMark"> — </span>Assessment of IDH mutational status and 1p/19q loss is required for all diffuse oligodendroglial and astrocytic tumors. <em>ATRX</em> expression is virtually always retained in oligodendrogliomas and most have telomerase reverse transcriptase (<em>TERT</em>) promoter mutations, whereas tumor protein p53 (<em>TP53</em>) mutations are rare in oligodendroglioma. Assessment of <em>ATRX</em> and <em>TP53</em> by immunohistochemistry is therefore sometimes used in gliomas with a proven IDH mutation to diagnose oligodendroglioma instead of assessment of 1p/19q codeletion status.</p><p class="headingAnchor" id="H2477869345"><span class="h3"><i>IDH1/2</i> mutational testing</span><span class="headingEndMark"> — </span>Mutations in <em>IDH1</em> and, less commonly, <em>IDH2</em> are a very early event in the tumorigenesis and a defining feature of the majority of WHO grade 2 and 3 diffuse gliomas. <em>IDH1/2</em> mutations can be present with and without 1p/19q codeletion. The combined presence of 1p and 19q loss defines oligodendroglioma, whereas <em>IDH1/2</em> mutation without 1p/19q codeletion is typical of diffuse astrocytomas [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/5223.html" rel="external">"Molecular pathogenesis of diffuse gliomas", section on 'Formation of oligodendroglial tumors'</a>.)</p><p>Immunohistochemical staining for the most common mutant form of <em>IDH1</em> (R132H), which identifies 90 percent of all IDH mutations, can be performed on all diffuse glioma specimens for diagnostic purposes as a first screen for IDH mutations. If R132H-mutant IDH1 immunohistochemistry is negative on a glioma specimen, sequencing of <em>IDH1</em> (codon 132) and <em>IDH2</em> (codon 172) for hotspot mutations must be performed, especially in the presence of astrocytic or oligodendroglial histologic features. In some centers, <em>IDH1/2</em> sequencing has replaced immunohistochemistry as the routine investigation for diffuse glioma specimens. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'IDH1/IDH2 mutation'</a>.)</p><p>Oligodendrogliomas with noncanonical<em> IDH1 </em>and <em>IDH2</em> mutations may have improved outcomes compared with <em>IDH1</em> R132H-mutant tumors [<a href="#rid14">14</a>]. However, this is not well established yet, and further studies are needed.</p><p class="headingAnchor" id="H2476102521"><span class="h3">Loss of 1p and 19q</span><span class="headingEndMark"> — </span>Combined loss of chromosome arms 1p and 19q, together with IDH mutation, defines oligodendroglioma. All diffuse gliomas should be tested for an IDH mutation, and all IDH-mutant gliomas should be tested for 1p/19q loss [<a href="#rid15">15</a>].</p><p>Loss of heterozygosity (LOH) studies including state-of-the-art next-generation sequencing panels and whole-genome methylation that assess multiple regions on 1p and 19q are the preferred tools to detect whole-arm 1p/19q codeletion [<a href="#rid16">16</a>]. Fluorescence in situ hybridization (FISH) alone is not an ideal technique because it does not assess loss of the entire arms of 1p and 19q.</p><p>Typical combined whole-arm loss of 1p and 19q is invariably associated with IDH mutation. Detection of 1p/19q codeletion by FISH in the absence of an IDH mutation (confirmed by <em>IDH1/2</em> sequencing) suggests loss of 1p and/or 19q as part of other copy number alterations and should prompt additional investigation for genetic changes associated with glioblastoma (in particular, gain of chromosome 7, loss of 10 or 10q, amplification of the epidermal growth factor receptor [<em>EGFR</em>] gene). (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on '1p/19q codeletion'</a>.)</p><p>The 1p/19q codeletion arises from an unbalanced translocation of the short arm of chromosome 19 (19p) to the long arm of chromosome 1 (1q), after which the derivative chromosome with the short arm of 1 and the long arm of 19 is lost [<a href="#rid17">17,18</a>]. In tumors in which this abnormality is identified, the deletions of 1p and 19q persist as the tumor progresses, suggesting that this translocation is an early event in tumorigenesis [<a href="#rid19">19</a>]. Additional chromosomal abnormalities are frequent in anaplastic oligodendroglial tumors [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/5223.html" rel="external">"Molecular pathogenesis of diffuse gliomas", section on 'Formation of glioblastoma and transition from low-grade to high-grade glioma'</a>.)</p><p>Among patients with grade 3 oligodendroglioma and the characteristic 1p/19q codeletion, the presence of polysomy of chromosomes 1 and 19 may identify a subset of patients with a poorer prognosis [<a href="#rid21">21,22</a>]. In a series of 46 patients with 1p/19q loss, those with polysomy had a significantly shorter median progression-free survival compared with those without polysomy (47 versus 87 months) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1038630789"><span class="h3"><i>CDKN2A/B</i> deletion</span><span class="headingEndMark"> — </span>Testing for the presence of homozygous <em>CDNK2A/B</em> deletion may be performed in IDH-mutant gliomas, including oligodendrogliomas. The presence of a deletion, although relatively uncommon in oligodendrogliomas (7 percent of 483 grade 3 oligodendrogliomas in one series), has been associated with shorter progression-free and overall survival, and it is consistent with a WHO grade 3 tumor but is virtually always observed in the presence of anaplastic features [<a href="#rid1">1,23</a>]. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Histopathologic and molecular classification'</a>.)</p><p class="headingAnchor" id="H2993053357"><span class="h3">Additional molecular testing</span><span class="headingEndMark"> — </span>Immunohistochemical staining for <em>ATRX</em> and mutant p53 expression is routinely performed on glioma specimens and can suggest the presence or absence of 1p/19q codeletion. <em>ATRX</em> mutation (indicated by loss of ATRX staining) and <em>TP53</em> gene mutation (indicated by positive p53 staining) are both common in astrocytomas and rare in oligodendrogliomas. Therefore, in the presence of an IDH mutation, the combination of retained ATRX expression and negative p53 staining is sometimes used to diagnose oligodendroglioma instead of assessment of 1p/19q codeletion status.</p><p>Virtually all oligodendrogliomas have the CpG island hypermethylated phenotype (CIMP), in which the O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) promoter region as a rule is also methylated. <em>MGMT</em> promoter methylation should be assessed in all glioblastoma specimens, but its clinical value in IDH-mutant gliomas is limited. Therefore, testing for <em>MGMT</em> promoter methylation status is not recommended for oligodendrogliomas [<a href="#rid15">15</a>].</p><p>Virtually all IDH-mutant, 1p/19q-codeleted oligodendrogliomas harbor a <em>TERT</em> mutation. <em>TERT</em> promoter mutations are not exclusive to oligodendroglioma, however, and their prognostic significance is dependent on the genetic background of the tumor. <em>TERT </em>promoter mutations in oligodendroglioma are mutually exclusive with mutations in <em>ATRX</em>, which occur in most IDH-mutant astrocytomas. When present in IDH-wildtype diffuse astrocytomas, <em>TERT</em> promoter mutations are associated with a poor prognosis, similar to that of glioblastoma.</p><p>Many oligodendrogliomas have additional mutations in the capicua transcriptional repressor (<em>CIC</em>) and far upstream binding element protein 1 (<em>FUBP1</em>) genes [<a href="#rid24">24,25</a>]. However, assessment of <em>CIC</em> and <em>FUBP1</em> does not have clinical relevance. The prognostic significance of <em>CIC</em> inactivating mutations in oligodendroglial tumors is unclear [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2946109307"><span class="h2">Tumors previously called oligoastrocytoma</span><span class="headingEndMark"> — </span>In the past, tumors containing histopathologic characteristics of both oligodendroglioma and astrocytoma were classified as oligoastrocytoma. Studies have shown if molecular criteria are applied, these tumors have either an oligodendroglial genotype (IDH mutated, 1p/19q codeleted) or an astrocytic genotype (IDH, <em>ATRX</em>, and <em>TP53</em> mutated) [<a href="#rid12">12</a>]. As a result, diffuse gliomas are characterized as either oligodendroglioma or astrocytoma [<a href="#rid1">1</a>]. Only if genetic testing fails or is not possible should the diagnosis of oligoastrocytoma NOS be made. True mixed tumors with genetic lesions reflecting both lineages are rare. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Oligoastrocytoma (historical entity)'</a>.)</p><p class="headingAnchor" id="H1977487987"><span class="h2">Mechanism of chemosensitivity</span><span class="headingEndMark"> — </span>The responsiveness of oligodendrogliomas to chemotherapy was initially observed in studies using the <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="9569" href="/d/drug information/9569.html" rel="external">lomustine</a>, and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (PCV) chemotherapy regimen in patients with recurrent tumors. Subsequent studies have shown a high response rate with single-agent <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> as well.</p><p>The mechanism underlying the chemosensitivity of oligodendrogliomas is an area of ongoing research. IDH mutations result in metabolic alterations, including decreased alpha-ketoglutarate (AKG), increased levels of 2-hydroxyglutarate (2HG), and changes in nicotinamide adenine dinucleotide phosphate (NADP) levels [<a href="#rid27">27</a>]. This leads to epigenetic alterations and the development of a CIMP, which as a rule includes <em>MGMT</em> promoter methylation [<a href="#rid28">28</a>]. MGMT is a nuclear enzyme responsible for DNA repair following alkylating-agent chemotherapy and may mediate part of the cellular resistance to alkylating agents. <em>MGMT</em> expression can be silenced by methylation of its promoter [<a href="#rid29">29</a>].</p><p>In parallel with the increase of 2HG, AKG levels are decreased. These changes are required for other resistance mechanisms against alkylating chemotherapy, such as AKG-dependent alkB homolog (ALKBH) DNA repair enzymes [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Oligodendroglial tumors are uncommon primary brain tumors, constituting approximately 5 percent of all neuroepithelial tumors of the central nervous system. They typically present in adults between 25 and 45 years of age but are occasionally diagnosed in teenagers and adults over the age of 65 years. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Oligodendrogliomas are slow-growing, infiltrative tumors that may be clinically silent for many years. The most common presenting symptom is seizure. Focal neurologic deficits are uncommon at the time of diagnosis. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – Most low-grade oligodendrogliomas have hyperintense or mixed signal on T2-weighted magnetic resonance imaging (MRI) and hypointense or mixed signal intensity on T1-weighted images  (<a class="graphic graphic_diagnosticimage graphicRef113599" href="/d/graphic/113599.html" rel="external">image 1</a>). Contrast enhancement is variable and does not necessarily indicate anaplastic (grade 3) pathology  (<a class="graphic graphic_diagnosticimage graphicRef140794" href="/d/graphic/140794.html" rel="external">image 2</a>). (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis requires an adequate tissue sample for histopathologic and molecular study, including testing for isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion  (<a class="graphic graphic_algorithm graphicRef134946" href="/d/graphic/134946.html" rel="external">algorithm 1</a>). Diagnostic tissue may be obtained by stereotactic biopsy for deep-seated tumors or at the time of maximal safe resection for tumors in accessible locations. Patients should be referred to a neurosurgeon with subspecialty expertise in brain tumor neurosurgery when possible. (See <a class="local">'Evaluation and diagnosis'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Pathologically, grade 2 and 3 oligodendrogliomas are genetically defined, diffusely infiltrating gliomas  (<a class="graphic graphic_picture graphicRef65601" href="/d/graphic/65601.html" rel="external">picture 1</a>) that contain both an <em>IDH1</em> or <em>IDH2</em> mutation and codeletion of chromosome arms 1p and 19q  (<a class="graphic graphic_algorithm graphicRef134946" href="/d/graphic/134946.html" rel="external">algorithm 1</a>). Retained nuclear <em>ATRX</em> expression and absence of a <em>TP53</em> mutation in an IDH-mutated glioma suggest 1p/19q codeletion. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemosensitivity</strong> – Compared with other diffuse gliomas, oligodendrogliomas are highly chemosensitive. The mechanism of chemosensitivity likely relates in large part to metabolically induced epigenetic changes, including CpG island hypermethylated phenotype (CIMP) and O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) promoter methylation. (See <a class="local">'Mechanism of chemosensitivity'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li><a class="nounderline abstract_t">Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol 2021; 23:iii1.</a></li><li><a class="nounderline abstract_t">Morshed RA, Han SJ, Hervey-Jumper SL, et al. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol 2019; 141:383.</a></li><li><a class="nounderline abstract_t">Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011; 13:649.</a></li><li><a class="nounderline abstract_t">Strickland BA, Cachia D, Jalali A, et al. Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. Neurosurgery 2016; 78:E466.</a></li><li><a class="nounderline abstract_t">Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 1989; 152:361.</a></li><li><a class="nounderline abstract_t">Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006; 129:1884.</a></li><li><a class="nounderline abstract_t">Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10:4303.</a></li><li><a class="nounderline abstract_t">Li M, Ren X, Chen X, et al. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma. Eur Radiol 2022; 32:3869.</a></li><li class="breakAll">Reifenberger G, Kros JM, Louis DN, Collins VN. Oligodendroglioma. In: World Health Organization Classification of Tumours, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon 2007. p.53.</li><li><a class="nounderline abstract_t">Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016; 131:803.</a></li><li><a class="nounderline abstract_t">Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014; 128:551.</a></li><li><a class="nounderline abstract_t">Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174:1149.</a></li><li><a class="nounderline abstract_t">Tesileanu CMS, Vallentgoed WR, Sanson M, et al. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 2021; 141:945.</a></li><li><a class="nounderline abstract_t">Brat DJ, Aldape K, Bridge JA, et al. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Arch Pathol Lab Med 2022; 146:547.</a></li><li><a class="nounderline abstract_t">McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev 2022; 3:CD013387.</a></li><li><a class="nounderline abstract_t">Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65:988.</a></li><li><a class="nounderline abstract_t">Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852.</a></li><li><a class="nounderline abstract_t">Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004; 63:314.</a></li><li><a class="nounderline abstract_t">Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999; 155:375.</a></li><li><a class="nounderline abstract_t">Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009; 15:6430.</a></li><li><a class="nounderline abstract_t">Jiang H, Ren X, Zhang Z, et al. Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neurooncol 2014; 120:131.</a></li><li><a class="nounderline abstract_t">Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 2019; 21:1519.</a></li><li><a class="nounderline abstract_t">Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 2016; 18:388.</a></li><li><a class="nounderline abstract_t">Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015; 129:133.</a></li><li><a class="nounderline abstract_t">Gleize V, Alentorn A, Connen de Kérillis L, et al. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol 2015; 78:355.</a></li><li><a class="nounderline abstract_t">Clark O, Yen K, Mellinghoff IK. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res 2016; 22:1837.</a></li><li><a class="nounderline abstract_t">van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 2013; 19:5513.</a></li><li><a class="nounderline abstract_t">Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002; 103:267.</a></li><li><a class="nounderline abstract_t">Wang P, Wu J, Ma S, et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep 2015; 13:2353.</a></li></ol></div><div id="topicVersionRevision">Topic 5186 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34608945" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30498891" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636710" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352098" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783515" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intracranial oligodendrogliomas: imaging findings in 35 untreated cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670176" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240515" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Imaging correlates of molecular signatures in oligodendrogliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35079884" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35079884" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157931" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25143301" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246647" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33740099" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175291" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35233774" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021403" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047046" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099021" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433931" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808867" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007776" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31832685" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354927" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427834" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26017892" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26819452" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23948976" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907807" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26686626" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
